22 min
Strategically Designed Drug Development & Personalised Care Programs: Emyria Limited (ASX: EMD) Meet The CEOs
-
- Investing
Emyria Limited (ASX: EMD) CEO Dr Michael Winlo discusses why the company is well positioned to rapidly and repeatedly develop new treatments as well as its key partnerships, recent achievements and strategic plans for the upcoming year.
Emyria Limited (ASX: EMD) is a data-backed, drug development company. Emyria’s Treatments target unmet needs and are focused on obtaining approval from major global regulators.
Any advice contained within this presentation is general advice and does not consider your objectives, financial situation or needs, and you should consider whether it’s appropriate for you. The information we are giving you is for educational purposes only.
Accurate time of recording, 17 February 2021, 12pm AEDT.
Emyria Limited (ASX: EMD) CEO Dr Michael Winlo discusses why the company is well positioned to rapidly and repeatedly develop new treatments as well as its key partnerships, recent achievements and strategic plans for the upcoming year.
Emyria Limited (ASX: EMD) is a data-backed, drug development company. Emyria’s Treatments target unmet needs and are focused on obtaining approval from major global regulators.
Any advice contained within this presentation is general advice and does not consider your objectives, financial situation or needs, and you should consider whether it’s appropriate for you. The information we are giving you is for educational purposes only.
Accurate time of recording, 17 February 2021, 12pm AEDT.
22 min